editing therapeutics to patients faster and more efficiently than ever before. We are seeking a highly skilled Research...: Experience with prime editing and base editing workflows. Expertise in CRISPR screening approaches, including CRISPR KO, CRISPRi...
. 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential... Join us in creating the future of genetic medicine. GENERAL SUMMARY 4D Molecular Therapeutics (4DMT), located in Emeryville...
Health Plan PrimeTherapeutics Blue Cross Blue Shield AL Blue Cross Blue Shield of AL High-Deductible Health Plan Bronze...
Lugar:
Tupelo, MS | 28/10/2026 18:10:36 PM | Salario: S/. $100000 - 130000 per year | Empresa:
ActalentDenali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the... an opportunity with Denali to help achieve our goal of delivering meaningful therapeutics to patients. This role leads clinical...
, with an emphasis on genetic medicines such as therapeutics, gene, base, or prime editing such as CRISPR/Cas, or viral vector gene...
Wolfe Laboratory is the development of genome editing tools, such as base editors and prime editors, to employ as new... classes of therapeutics. The successful candidate would be a part of an interdisciplinary team of laboratory scientists...
National payers including United Health/Optum/Emisar, Humana, and PrimeTherapeutics. The ADNA will be directly responsible...
managed care strategies with key National payers including United Health/Optum/Emisar, Humana, and PrimeTherapeutics. The...
and prime editors, to employ as new classes of therapeutics. The successful candidate would be a part of an interdisciplinary... team of laboratory scientists, clinicians, and computational biologists that are working on therapeutics for a variety...
Design) to join us in our mission to transform the discovery of therapeutics and materials! Schrödinger has pioneered... team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics...